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Platforms able to storage, release or scavenge NO in a controlled and specific manner is 
interesting for biological applications. Among the possible matrices for these purposes, 
dendrimers are excellent candidates for that. These molecules have been used as drug 
delivery systems and exhibit interesting properties, like the possibility to perform chemical 
modifications on dendrimers surface, the capacity of storage high concentrations of 
compounds of interest in the same molecule and the ability to improve the solubility and 
the biocompatibility of the compounds bonded to it. This review emphasizes the recent 
progress in the development and in the biological applications of different NO-releasing 
dendrimers and the nitric oxide release pathways in these compounds.
Uniterms: Dendrimer. Nitric oxide. Nitrosyl complexes. Diazeniumdiolate. Nitrosothiol.
Plataformas capazes de armazenar, liberar ou capturar NO de forma controlada e específica 
são de grande interesse tendo-se em vista aplicações biológicas. Dentre as possíveis 
matrizes que podem ser utilizadas para esse fim, os dendrímeros são excelentes candidatos. 
Essas moléculas têm sido empregadas em sistemas para o transporte de fármacos e 
apresentam propriedades interessantes tais como a possibilidade de modificações químicas 
em sua superfície, a capacidade de estocar altas concentrações de compostos de interesse 
em uma só molécula e a possibilidade de aumentar a solubilidade e a biocompatibilidade 
dos compostos a eles ligados. Esta revisão enfatiza os recentes avanços no desenvolvimento 
e nas aplicações biológicas de diferentes dendrímeros liberadores de NO e a forma em 
que o óxido nítrico é liberado nesses compostos.
Unitermos: Dendrímero. Óxido nítrico. Nitrosilo complexos. Diazeniodiolato. Nitrosotiol.
INTRODUCTION
Chemical, biological (Fukuto et al., 2012; Toledo, Augusto, 2012) 
and medical aspects of nitric oxide (NO) have been subject of great interest 
since the discovery that mammalian cells are able to synthesize it (Palmer, 
Ashton, Moncada, 1988; Pagliaro, 2003; Pacher, Beckman, Liaudet, 2007). 
This uncharged diatomic molecule is generated endogenously by three nitric 
oxide synthases (NOS) enzymes – endothelial NOS, neuronal NOS and in-
ducible NOS – which catalyses the conversion of L-arginine to L-citrulline, 
yielding NO (Palmer, Ashton, Moncada, 1988; Ignarro, 1990; Zweier et 
al., 1995; Zhou, Zhu, 2009). Nitric oxide, a small molecule signaling agent 
(Fukuto et al., 2012), is associated with many biological processes (Toledo, 
Augusto, 2012) as vasodilatation (Furchgott, Zawadzki, 1980; Hu et al., 
2003; Yetik-Anacak, Catravas, 2006; Pacher, Beckman, Liaudet, 2007), 
immune response (Bogdan, 2001; Bogdan, Röllinghoff, Diefenbach, 2000; 
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Karpuzoglu, Ahmed, 2006), as regulator of the central and 
peripheral nervous system (Bredt, Hwang, Snyder, 1990; 
Garthwaite, 1991, 1995; Moncada, Palmer, Higgs 1991; 
Steinert, Chernova, Forsythe, 2010), angiogenesis and 
muscle contractility (Reid, 2001; Stamler, Meissner, 2001).
Due to the properties outlined above, an exogenous 
NO deliver is a potential therapeutic agent, inasmuch de-
ficiencies in NO biosynthesis are related to some diseases 
(Baylis, 2008; Luiking, Engelen, Deutz, 2010). NO can 
be administered in gaseous form (respiratory route) in 
specific cases (Serafim et al., 2012), but this compound is 
known to react with a wide number of molecules (proteins, 
thiols, heme proteins, metals and others) and also can be 
oxidized in solution to NO2 by O2 (Fukuto et al., 2012; 
Toledo, Augusto, 2012). In addition, the NO lifetime in 
biological media varies from 10 ms to 1 sec (Thomas et al., 
2001; Flores-Santana et al., 2009). Furthermore local lack 
or excess of NO can be deleterious for biological systems. 
Therefore, strategies to produce stable NO carriers systems 
have been developed, being much of the work focused on 
the synthesis of nitric oxide donors (NO-donors) (Wang 
et al., 2002; Serafim et al., 2012) or scavengers (Fricker 
et al., 1997; Davies et al., 1997).
There are some representative chemical classes 
of NO-donors (Figure 1), as S-nitrosothiols (RSNOs), 
diazeniumdiolates (NONOates), organic nitrates and ni-
trites, and metal nitrosyl complexes, which were recently 
reviewed (Miller, Megson, 2007; Keefer, 2011; Tfouni et 
al., 2012; Serafim et al., 2012).
Most of synthesized NO-releasing compounds have 
been used to help in understanding the physiologic aspects 
related to NO and to describe its therapeutic properties. 
This last topic includes as examples the protection of 
myocardium against ischemia/reperfusion injuries (Chan, 
2002; Webb et al., 2004; Schulz, Kelm, Heusch, 2004), 
toxicity toward cancer cells (Osti et al., 2012; Serafim 
et al., 2012), trypanocidal and leishmanicidal activities 
(Silva et al., 2007, 2009; Pereira et al., 2010; Guedes et 
al., 2010; Tfouni et al., 2012).
A reasonable volume of the current research have 
been focused on attaching NO releasing compounds to dif-
ferent platforms (Eroy-Reveles, Mascharak, 2010; Tfouni 
et al., 2010; Seabra, Durán, 2010; Riccio, Schoenfisch, 
2012; Jen et al., 2012), as nanoparticles (Friedman et al., 
2008; Seabra, Durán, 2010), silica gel (Zanichelli, Serna-
glia, Franco, 2006; Doro, Rodrigues-Filho, Tfouni, 2007), 
xerogels and dendrimers (Stasko, Schoenfisch, 2006; 
Stasko, Fischer, Schoenfisch, 2008; Benini, McGarvey, 
Franco, 2008; Lu et al., 2011). These strategies aimed to 
improve NO-donors stability (Lu et al., 2011), promote a 
high payload of nitric oxide on a single platform (Stasko, 
Schoenfisch, 2006; Stasko, Fischer, Schoenfisch, 2008) 
and achieve specific targets (Taite, West, 2006).
In this context, next topics deal specifically with 
functionalized dendrimers, tailored for NO delivery and 
their possible applications.
Dendrimers as a platform for NO transport
Dendrimers are molecules of the dendritic materials 
group, which is also composed by dendronized and hyper-
branched polymers, dendrons and dandrigrafts (Carlmark 
et al., 2009; Astruc, Boisselier, Ornelas, 2010). The main 
difference between dendrimers and dendrons regarding to 
the other dendritic polymers is related to their shape: den-
drimers and dendrons are perfectly branched (Figure 2).
The concept of dendrimer-like compound was first 
described by Vögtle and coworkers (Buhleier, Wehner, 
FIGURE 2 - Schematic picture of dendrons (A) and dendrimer 
(B). Gn (n=0–2) represent dendrimer generations: generation 
0 to 2.
FIGURE 1 - Representative NO-donors: (a) metal nitrosyl, (b) 
organic nitrates, (c) S-nitrosothiols and (d) diazeniumdiolates.
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Vögtle, 1978), who synthesized polypropyleneimine 
(PPI), employing branching trough repetitive growth 
approach. The first dendrimer synthesis was carried out 
independently by two groups of researchers: Tomalia and 
coworkers (1985) and Newkome and coworkers (1985), 
whose “baptize” their molecules as “starburst polymer” and 
“arborol”, respectively. Dendrimers are generally described 
as hyperbranched molecules, with a well defined structure, 
possessing three main architectural components (Figure 
2B): core, interior layers (radially branched) which define 
dendrimers generations and end-groups (surface or exterior) 
(Tomalia et al., 1985).
One of the key features related to dendrimers is 
the possibility of tailoring its surface through chemical 
modifications, and their conjugation with molecules or 
ions of interest (Astruc, Boisselier, Ornelas, 2010; Archut 
et al., 1998; Vögtle et al., 1999). Major applications are 
related to the drug delivery systems development (Gillies, 
Fréchet, 2005; Medina, El-Sayed, 2009; Nanjwade et al., 
2009; Wijagkanalan, Kawakami, Hashida, 2011; Sun et al., 
2012), solubility (Devarakonda, Hill, Villiers, 2004) and 
biocompatibility improvements (reduce toxicity) (Dun-
can, Izzo, 2005; Sadekar, Ghandehari, 2010; Ciolkowski 
et al., 2012), magnetic resonance image (MRI) contrast 
(Wiener et al., 1994; Margerum et al., 1997; Kobayashi et 
al., 2003; Kojima et al., 2011; Tang et al., 2012), targeted 
drug delivery (Yang et al., 2009; Menjoge et al., 2011) and 
gene delivery (Dufès, Uchegbu, Schätzlein, 2005; Kim et 
al., 2007; Mintzer, Simanek, 2009; Shcharbin, Klajnert, 
Bryszewska, 2009; Nam et al., 2012).
The most common dendrimers (Newkome, Shreiner, 
2008; Mintzer, Grinstaff, 2011) are polyamidoamine 
(PAMAM), polyamide, poly(L-lysine) (PLL), polypro-
pylenimine (PPI) and PEG-polyester types, being most 
of them commercially available.
Together with other types of matrices (Tfouni et al., 
2010; Seabra, Durán, 2010; Saraiva et al., 2011; Riccio, 
Schoenfisch, 2012), dendrimers have been used as NO-
releasing carriers platforms (Taite, West, 2006; Stasko, 
Schoenfisch, 2006; Stasko, Fischer, Schoenfisch, 2008; 
Benini, McGarvey, Franco, 2008; Lu et al., 2011). One 
of the advantages of the NO-donors dendrimers over 
others NO carriers systems is their ability of storage high 
concentrations of nitric oxide per unit of drug carrier. For 
example Stasko (Stasko, Schoenfisch, 2006) synthesized 
polypropylenimine (PPI) dendrimers of generations 3 
and 5 conjugated with diazeniumdiolates (Figure 3 and 
Table I, compounds 1-7). The highest NO storage capac-
ity (5.6 µmol NO mg-1) was achieved with the secondary 
amine dendrimer 1 (DAB-PO-64/NO), followed by 6 (3.4 
µmol NO mg-1) and 7 (3.2 µmol NO mg-1), which were 
more stable than the ones containing primary amines (4, 5) 
and amides (2, 3) (Stasko, Schoenfisch, 2006). Syntheses 
of diazeniumdiolate-dendrimers (1-7) were performed 
using high pressure of NO gas (5 atm) in basic solution to 
convert primary (4, 5), secondary amines (1, 6 and 7) and 
amides (2, 3) to diazeniumdiolates (Stasko, Schoenfisch, 
2006). Secondary amines (1, 6, 7) provided better conver-
sion to diazeniumdiolates than primary amines (4, 5) and 
amides (2, 3), as shown in Table I.
Also, PAMAM dendrimers were used as NO-releas-
ing carriers. Stasko (Stasko, Fischer, Schoenfisch, 2008) 
synthesized two types of PAMAM dendrimer generation 
4, with S-nitroso-N-acetyl-L-cysteine (NACysNO) or S-
nitrosothiol-N-acetyl-D,L-penicillamine (SNAP) groups 
respectively attached to its surface (Figure 4 and Table I, 
compounds 8 and 9, respectively). The capacity of nitric ox-
ide storage of the two above S-nitrosothiol dendrimers was 
2.1 ± 0.2 µmol NO mg-1 for 8 and 1.7 ± 0.2 µmol NO mg-1 
for 9 (Stasko, Fischer, Schoenfisch, 2008).
Taite and West  (2006) have synthesized a 
poly(ethyleneglycol)-lysine (PEG-lys) dendrimer in which 
multiple diazeniumdiolate NO-donors were generated by 
FIGURE 3 - Structure of (A) PPI dendrimer generation 3 and 
(B) PPI diazeniumdiolates (adapted from Stasko, Schoenfisch, 
2006).
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TABLE I - General properties of NO-releasing dendrimers
NO-releasing
dendrimer
Class of
NO donor
NO-release
mechanism
t1/2 (min)
(half-life of NO 
release)
Number of
dendrimer
superficial
groups
% of NO
conjugated
on the 
dendrimer 
surface
References
DAB-PO-64/NO (1) 
Spontaneous in
physiologic 
condition
28 64 47 a
(Stasko, 
Schoenfisch, 
2006)
DAB-Ac-16/NO (2) 1.4 16 <0.2 a
DAB-Ac-64/NO (3) 2.5 64 <0.2 a
DAB-Am-16/NO (4) Diazeniumdiolate 12 16 2.3 a
DAB-Am-64/NO (5) 29 64 3.9 a
DAB-C7-16/NO (6) 77 16 38 a
DAB-C7-64/NO (7) 86 64 36 a
G4-NACysNO (8)
G4-SNAP (9) S-nitrosothiol
Triggered by light 
and/or copper
7–106 b
1.5–200 b
63 c / 62 ± 2 d
58 c / 49 ± 4 d
87 e
79 e
(Stasko, Fischer, 
Schoenfisch, 2008)
PEG-lys NO (10) Diazeniumdiolate
Spontaneous in
physiologic 
condition
ND ND 83 ± 9 
a
(Taite, West, 2006)
G0/RuNO (11)
Metal-nitrosyl 
complex
(ruthenium)
Triggered by 
chemical reduction 
or light irradiation
4.12–6.08 f 4 100 (Benini, McGarvey, Franco, 2008)
G2/RuNO (12) 3.98–8.25 f 16 75
G3/RuNO (13) ND 32 90.6
a-8-NO G2-PPI-ACN-NO (14) Diazeniumdiolate
Spontaneous in
physiologic 
condition
288.6 8 26.1 a (Lu et al., 2011)
a-16-NO G3-PPI-ACN-NO (15) 290.4 16 26.1 a
a-32-NO G4-PPI-ACN-NO (16) 289.2 32 19.9 a
a-64-NO G5-PPI-ACN-NO (17) 292.8 64 13.8 a
b-8-NO G2-PPI-PEG-NO (18)
Spontaneous in
physiologic 
condition
40.2 8 31.9 a (Lu et al., 2011)
b-16-NO G3-PPI-PEG-NO (19) 66.6 16 31.6 a
b-32-NO G4-PPI-PEG-NO (20) 50.4 32 40.3 a
b-64-NO G5-PPI-PEG-NO (21) 73.2 64 34.6 a
c-8-NO G2-PPI-PO-NO (22) 18 8 22.7 a
c-16-NO G3-PPI-PO-NO (23) 37.2 16 26.2 a
c-32-NO G4-PPI-PO-NO (24) 46.8 32 27.3 a
c-64-NO G5-PPI-PO-NO (25)* Diazeniumdiolate 63.6 64 32.1 a
d-8-NO G2-PPI-SO-NO (26) 88.2 8 12.2 a
d-16-NO G3-PPI-SO-NO (27) 58.2 16 10.3 a
d-32-NO G4-PPI-SO-NO (28) 85.8 32 13.6 a
d-64-NO G5-PPI-SO-NO (29) 97.2 64 14.5 a
e-8-NO G2-PPI-ED-NO (30) 48.6 8 24.2 a
e-16-NO G3-PPI-ED-NO (31) 102.6 16 21.1 a
e-32-NO G4-PPI-ED-NO (32) 80.4 32 19.9 a
e-64-NO G5-PPI-ED-NO (33) 112.8 64 24.7 a
a values based on the conversion efficiency of amine or amide precursor to diazeniumdiolates. b depending on the trigger type (Stasko, Fischer, 
Schoenfisch, 2008). c number of thiol (NAP)/dendrimer estimated by 1H NMR (the original PAMAM dendrimer has 64 end groups) (Stasko, Fischer, 
Schoenfisch, 2008). d number of thiol (NAP)/dendrimer estimated by Ellman´s assay (Stasko, Fischer, Schoenfisch, 2008). e estimated by the yield of 
NO storage efficiency (Stasko, Fischer, Schoenfisch, 2008). f estimated from the kobs values in different pH. * similar structure of compound 1.
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the reaction of PEG-lys with NO gas (Table I, compound 
10). This reaction converted ~83 ± 9% of amines in dia-
zeniumdiolate NO-donors.
Benini, McGarvey and Franco (2008) have func-
tionalized PAMAM dendrimers of generation 0, 2 and 3 
with the complex K[Ru(edta)Cl]. The functionalization 
was performed through a peptide bond between one of 
the carboxylate arms of the edta ligand and the superficial 
amines of dendrimers. This anchored chloro complex 
in aqueous solution yields the respective aquo species 
[Ru(edta)H2O]- attached to the dendrimer surface. The 
reaction of this system with NO gas (6 h) yielded the NO 
analogous species [Ru(edta)NO]-, which remain anchored 
on PAMAM (Figure 5 and Table I, compounds 11-13). The 
percentage of superficial groups of PAMAM functional-
ized with ruthenium complexes were 100% for G0, 75% 
for G2 and 90.6% for G3 (Benini, McGarvey, Franco, 
2008). According to the reported data (Benini, McGarvey, 
Franco, 2008), compound 13 was able to storage ~1.4 
µmol NO mg-1.
In addition, PAMAM dendrimer functionalized 
with [Ru(edta)H2O]- can be used as nitric oxide scav-
enger, once [Ru(edta)H2O]- reacts with NO to produce 
[Ru(edta)NO]- at the second order rate constant of 
~2 x 107 M-1 s-1 in phosphate buffer at pH = 7.4 and 7.3 ºC 
(Davies et al., 1997; Wanat et al., 2002). NO scavengers 
were proposed as therapeutic agents for septic shock treat-
ment (Davies et al., 1997, Fricker et al., 1997; Cameron et 
al., 2003), and dendrimers functionalized with [Ru(edta)
H2O]- could also be used for this purpose (Benini, McGar-
vey, Franco, 2008).
Lu et al. (2011) synthesized a series of amine PPI 
dendrimers (generation 2–5) functionalized with different 
surface groups (acrylonitrile = ACN, propylene oxide = 
PO, styrene oxide = SO or poly(ethylene glyclol) methyl 
ether acrylate = PEG and 1,2-epoxy-9-decene = ED). The 
authors reacted these compounds with NO gas (10 atm of 
NO in a methanolic sodium methoxide solution) to pro-
duce the respective diazeniumdiolates on the resulting sec-
ondary amine G2–G5 PPI (Figure 6, Table I, compounds 
14-33). The NO storage capacity of compounds 14-33 was 
in the range of 0.9–3.8 µmol NO mg-1(Lu et al., 2011), 
showing how dendrimer surface modifications influence 
the diazeniumdiolate properties (stability/release of NO).
Following a similar approach, Sun et al. (2012) 
functionalized PPI dendrimers of generation 2 and 5 with 
PEG, PO or SO, and then reacted the products with NO gas 
(10 atm, in sodium methoxide solution in methanol) to ob-
tain compounds of similar structure of 18 and 21 for PEG, 
22 and 25 for PO and 26 and 29 for the SO PPI function-
alized dendrimer (Figure 6). The NO storage capacity of 
these compounds was in the range of 1.8-3.8 µmol NO mg-1 
and the conversion efficiency of amines into diazenium-
diolates, between 19–35% (Sun et al., 2012). Antibacterial 
activity of these compounds was tested against Gram-
positive and Gram-negative pathogenic bacteria (Sun et 
al., 2012), and it will be discussed in next sections.
NO-donors dendrimers: mechanism of nitric 
oxide release
One of the main differences observed among the 
NO-releasing dendrimers is their nitric oxide release 
FIGURE 4 - Representation of PAMAM dendrimer with 
S-nitrosothiols (adapted from Stasko, Fischer, Schoenfisch, 
2008).
FIGURE 5 - PAMAM dendrimer generation 2 (G2/RuNO) 
functionalized with [Ru(edta)NO]-. (Benini, McGarvey, Franco, 
2008).
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mechanism (see Table I). All diazeniumdiolate derivative 
dendrimers (1-7, 10, 14-33 on Table I) release NO spon-
taneously under physiological conditions (pH 7.4, 37 ºC), 
yielding two moles of NO per mole of diazeniumdiolate 
(Figure 7) (Davies et al., 2001; Hrabie, Keefer, 2002; 
Keefer, 2011).
Nitric oxide release in these dendrimer-diazenium-
diolates derivatives occurs through a hydrolytic degrada-
tion mechanism, initiated by protonation at the amine ni-
trogen (Davies et al., 2001; Hrabie, Keefer, 2002; Keefer, 
2011). Compound 1 and 7 (Figure 3) were able to maintain 
the sustained-release of NO for more than 16 h, followed 
by 6 (~14h), being these values the longest observed 
among analogous compounds (dendrimers 2-5) and small 
alkyl diazeniumdiolates (Stasko, Schoenfisch, 2006). The 
great increase on the NO release duration time, in com-
parison with small alkyl diazeniumdiolates, was attributed 
to the dendritic effect (Stasko, Schoenfisch, 2006), which 
resulted in an enhancement on the diazeniumdiolate stabil-
ity. This effect was also correlated with the increase in the 
NO release half-life (t1/2) of NO-releasing dendrimers in 
comparison to the structural equivalent small molecules 
(Stasko, Schoenfisch, 2006).
In the other series of diazeniumdiolate PPI den-
drimers (14-33, Figure 6), compounds 14-17 released NO 
for ~25 h, 18-21 for ~21 h, 22-25 for ~22 h, 26-29 for ~17 h 
and 30-33 for ~22 h (Lu et al., 2011). For compounds 14-
33, the NO release kinetics presented a wide range of t1/2 
values, which varied from 18 to 293 min (Table 1). This 
broad range of values for t1/2 was explained based on the 
dendrimers exterior modifications. Faster NO release (in 
general) observed for compounds 18-25 in comparison 
to others of this class (14-17 and 26-33) was attributed to 
the presence of PEG (18-21) or PO (22-25) groups on the 
dendrimers surface (Figure 6), which are hydrophilic and 
consequently facilitate the diazeniumdiolate degradation 
and the NO release (Lu et al., 2011). This explanation was 
consistent with the measured t1/2 values for NO release 
from compounds 26-33, which have more hydrophobic 
surface groups at the exterior of dendrimer (SO or ED, 
Figure 6), thus resulting in higher t1/2 values than the ones 
observed for compounds 18-25.
It is interesting to note that despite the foregoing, 
the longest t1/2 values for NO release in the series of 
diazeniumdiolate PPI dendrimers were observed for the 
compounds 14-17, which have a hydrophilic cyano group 
on the dendrimer surface. According to the authors (Lu et 
al., 2011), cationic groups on the neighboring of diazeni-
umdiolates are responsible for the additional stabilization 
of this class of NO-donors, thus increasing the t1/2 values 
for NO release.
Also, Taite and West (2006) have synthesized an-
other diazeniumdiolate dendrimer (10) that release NO 
for over 60 days period under physiological conditions, 
with the majority of the release occurring within the first 
10 days.
According to Stasko, Fischer, Schoenfisch (2008) 
S-nitrosothiol (RSNO) derivative dendrimers (8, 9) are 
able to release nitric oxide by two main pathways (Figure 
8): (A) transition metal-mediated catalytic decomposition, 
based on Cu+/Cu2+ redox couple and (B) photo-initiated 
decomposition. In the last pathway, irradiation of com-
pounds 8 and 9 using a broad-spectrum white light resulted 
in homolytic cleavage of the S–N bond, generating a thiyl 
radical (RS•) and also liberating NO (Stasko, Fischer, 
Schoenfisch, 2008).
FIGURE 6 - Schematic representation of PPI dendrimer 
functionalized with different ligands and diazeniumdiolates 
(adapted from Lu et al., 2011; Sun, et al., 2012).
FIGURE 7 - NO release from diazeniumdiolate under 
physiological conditions.
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The rate constant for NO release was dependent on 
the structure of the nitrosothiol (SNAP or NACysNO) and 
on the NO release triggers (copper or light). This resulted 
in t1/2 values for NO dissociation in the range of 7–106 min 
for 8 and 1.5-2.3 min for 9 when triggered by copper (0.2, 
0.6 or 1 mM of Cu2+), and 49–97 min for 8 and 34-200 min 
for 9 when triggered by light (60, 100 or 200 W) (Stasko, 
Fischer, Schoenfisch, 2008).
PAMAM dendrimers functionalized with ruthenium 
NO-donors (11-13) release nitric oxide after one-electron 
reduction, following a pathway similar to the other ruthe-
nium nitrosyl complexes (Borges et al., 1998; Gomes et 
al., 1998; Tfouni et al., 2003; Carlos et al., 2004; Toledo 
et al., 2002, 2004; Metzker, Cardoso, Franco, 2013). 
According to Benini, McGarvey and Franco (2008) the 
reaction of compounds 11-13 with Eu(II) liberates NO 
(Figure 9), similarly to the analogous free ruthenium ni-
trosyl complexes (not attached on PAMAM): the nitrosyl 
ligand (NO+) is first reduced to NO0 and then dissociates 
from the ruthenium coordination sphere (Benini, Mc-
Garvey, Franco, 2008). Dissociation is the reaction rate 
determining step.
It is interesting to highlight that the chemical prop-
erties of ruthenium nitrosyl complexes were not altered 
after their attachment to the PAMAM dendrimers (Benini, 
McGarvey, Franco, 2008). The potential for the nitrosyl 
reduction (NO+/NO0) in the compounds 11-13 was around 
-0.32 V vs SCE (saturated calomel electrode), values 
which are very close to the ones measured for the complex 
[Ru(edta)NO]- (-0.34 V vs SCE). These redox potentials 
are accessible for the reducing agents as NADH, NADPH 
and cysteine present in biological media, thus enabling the 
in vivo delivery of NO from these metal nitrosyls. Also, the 
rate constants for NO release (k-NO) in compounds 11 and 
12 after one-electron reduction were in the range of 1.9–
2.9 x 10-3 s-1, which is in agreement with the previously 
FIGURE 9 - Nitric oxide release from ruthenium nitrosyl 
dendrimer (Benini, McGarvey, Franco, 2008).
reported (Zanichelli et al., 2004) k-NO value of 2.1 ± 0.4 x 
10-3 s-1 for [Ru(Hedta)NO] (pH 1.0, 25 ºC). Compounds 11 
and 12 showed t1/2 values for NO release (after one electron 
reduction) in the range of 4.0-8.2 min (Table I) (Benini, 
McGarvey, Franco, 2008), which is in agreement with t1/2 
data for NO release for [Ru(Hedta)NO], that is ~5.5 min 
(Zanichelli et al., 2004).
All together, the general features of the nitric oxide 
release mechanisms for all NO-donors presented above 
(diazeniumdiolates, S-nitrosothiol and metal nitrosyl 
complexes) were maintained when these compounds were 
attached to dendrimers.
Applications of NO-releasing dendrimers
Most of NO-releasing dendrimers discussed above 
were tested in different biological assays (Taite, West, 
2006; Benini, McGarvey, Franco, 2008; Stasko, Fischer, 
Schoenfisch, 2008; Johnson et al., 2010; Sun et al., 
2012). Stasko, Fischer and Schoenfisch (2008) described 
the ability of S-nitrosothiol derivative dendrimer 9 in 
the inhibition of thrombin-mediated platelet aggrega-
tion. According to the authors, the mechanism occurs 
via transnitrosation (Hogg, 2000; Walsh et al., 2007; 
Bell, Shah, Gordge, 2007; Stasko, Fischer, Schoenfisch, 
2008), a process in which a nitrosothiol transfers the 
nitroso group to a free thiol (present in proteins on the 
platelet surface). Compound 9 inhibited platelet aggre-
gation regardless of nitrosothiol (SNAP) concentration 
(100, 50 or 25 mM), and at 25 mM led to a reduction of 
62% in the aggregation compared to 17% for 25 mM of 
the analogous small molecule (similar S-nitrosothiol – 
SNAP – not attached on dendrimer). Best results for 9 
in comparison to the “free” SNAP were attributed by the 
authors to the increase on the S-nitrosothiols local con-
centration during the transnitrosation process, due to the 
anchoring of the dendrimer on the cell surface (Stasko, 
Fischer, Schoenfisch, 2008).
Taite and West (2006) tested the capacity of com-
pound 10 on the inhibition of platelet adhesion to throm-
bogenic surfaces. PEG-lys-NO dendrimers (10) reduced 
platelet adhesion in approximately 81% regarding to the 
analogous dendrimer that did not carry NO (PEG-Lys) (Ta-
ite, West, 2006). Another assay was performed to verify the 
ability of compound 10 on the regulation of vascular cell 
proliferation (Taite, West, 2006). First, cell viability was 
assessed using culture of bovine aortic endothelial cells 
(BAECs) and rat aortic smooth cells (SMSc), which were 
exposed to NO-releasing dendrimers (10, PEG-Lys-NO) 
and to ones that do not release NO (PEG-Lys). According 
to the authors, the NO-releasing dendrimer 10 is non toxic 
FIGURE 8 - General mechanism of nitrosothiol decomposition 
and NO release, (A) copper-mediated and (B) photo-initiated 
(adapted from Stasko, Fischer, Schoenfisch, 2008).
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for BAECs (100 ± 1% of cell viability) and SMCs (99 ± 
3% of cell viability). The same test performed with PEG-
Lys, resulted in cell viability of 89 ± 3% for BAECs and 
87 ± 6% for SMCs. As reported (Taite, West, 2006) this 
result showed that even the PEG-Lys low toxicity is re-
duced when NO is linked to the dendrimer (PEG-Lys-NO, 
10). They also demonstrated the ability of compound 10 
to selectively target an inflamed endothelium (compound 
10 modified with a targeting ligand specific for inflamed 
endothelium – Sialyl Lewis X), as an example of the 
significant therapeutic potential of such NO-releasing 
dendrimer.
Johnson et al. (2010) reported the activity of S-
nitrosothiol dendrimer 9 (G4-SNAP) in reducing ischemia/
reperfusion injury. Using the same concentration of S-ni-
trosothiol (2 mM of SNAP) in G4-SNAP and in free SNAP 
(not attached on dendrimer), the infarct percentage (% in-
farct) was respectively of 3.48 ± 0.46% and 4.41 ± 1.45% 
(not statistically different). These values were lower than 
the exhibited by control (similar molecules that do not 
delivery NO: G4-NAP and NAP), in which the % infarct 
was around 11% (Johnson et al., 2010).
Acute toxicity of 9 was evaluated on human um-
bilical vein endothelial cells (HUVEC) and pulmonary 
artery endothelial cells (CPA-47), using two different 
assays: propidium iodide uptake (PI) and the release of 
lactate dehydrogenase (LDH). Results demonstrated the 
low cytotoxicity of compound 9 in two concentrations 
(4 and 40 mM) after two hours of exposure: the HUVEC 
viability was in the range of 89.1–92.7% and the CPA-47 
in the range of 87.7-92.3% (in both PI and LDH tests) 
(Johnson et al., 2010).
The same authors (Johnson et al., 2010) also evalu-
ated the kinetics aspects of nitric oxide release from com-
pound 9 (300 nM) initiated by different concentrations 
(10, 2, 1, 0.5 mM) of glutathione (GSH). The higher rate 
for NO release was achieved with 0.5 mM of GSH, result-
ing in a maximum flux of 1429 ppb NO mg-1 s-1 after 45 
min. In addition, reperfusion experiments performed with 
GSH (0.5 mM) and G4-SNAP together (varying the con-
centration between 23 pM–31 nM) resulted in an optimal 
therapeutic dose of 0.23 nM of G4-SNAP (i.e., 15 nM of 
SNAP). This result represents a 133 fold lower dose in 
comparison to the free SNAP optimal dose (2 mM), and 
led to only 2.34 ± 0.9 % infarct (Johnson et al., 2010).
Benini, McGarvey and Franco (2008) evaluated the 
relaxation effects of ruthenium nitrosyl dendrimers (11 and 
13) in denuded normotensive rat aortic rings (precontract-
ed with noradrenaline). Slow delayed relaxation started 
after 15 min (14.1 ± 6.2% induced by compounds 11 and 
13, at a concentration of 3 mM of the ruthenium nitrosyl) 
and the maximum relaxation (36.8 ± 6.5%) was achieved 
in the second hour. This is on agreement with the behav-
ior observed for [Ru(edta)NO]- in solution, for which the 
maximal relaxation effect in the second hour was 62.3 ± 
16.5%. Compound 11 was also evaluated regarding to its 
trypanocidal activity in vitro against drug-resistant strain 
(Y strain) of Trypanosoma cruzi. At the concentration of 
1.0 mM (in relation to ruthenium nitrosyl), 100% of typo-
mastigote forms of the parasite were killed, in comparison 
to the 89% of activity exhibited by [Ru(edta)NO]- not 
attached to the dendrimer (Benini, McGarvey, Franco, 
2008). The trypanocidal effect was attributed to NO re-
lease, once the non NO-releasing complex [RuIII(edta)
(H2O)]- did not exhibited any activity (Benini, McGarvey, 
Franco, 2008).
Sun (2012) evaluated the antibacterial activity 
of compounds 18, 21, 22, 25, 26, 29 (see Figure 6 and 
Table 1) and each respective precursor (dendrimer with-
out diazeniumdiolate moiety – non NO-releasing den-
drimers, described for simplicity as 18a, 21a, 22a, 25a, 
26a, 29a) against Pseudomonas aeruginosa (Gram-neg-
ative), standard Staphylococcus aureus (Gram-positive) 
and antibiotic-resistant (methicillin) S. aureus (MRSA). 
In general, the concentration of NO-releasing dendrimers 
needed to kill completely P. aeruginosa was lower than 
the one required by the respective non NO-releasing den-
drimers. Similar results were observed for Gram-positive 
S. aureus, except for the dendrimer functionalized with 
PO, in which bactericidal efficacy of compound 22a (non 
NO-releasing dendrimer) was greater than for 22 (NO-
releasing dendrimer). This behavior was attributed to the 
negative zeta potential (ζ) value for the NO-releasing 22 
(-14.0 ± 5.4 mV) in comparison to the positive value for 
22a (7.1 ± 0.6 mV) (Sun, et al., 2012). Once bacterial 
membrane is negatively charged, interactions with mol-
ecules with more positive ζ are expected to be enhanced, 
improving the efficiency of these compounds (Sun et 
al., 2012). NO-releasing dendrimers (18, 21, 22, 25, 26, 
29) also presented greater bactericidal efficacy against 
antibiotic-resistant S. aureus (MRSA) than the respec-
tive non NO-releasing species (18a, 21a, 22a, 25a, 26a, 
29a) (Sun et al., 2012). Nitric oxide bactericidal activity 
was attributed to NO byproducts such as peroxynitrite 
(ONOO-) and dinitrogen trioxide (N2O3) which would 
drive the oxidative and the nitrosative stress (Sun et al., 
2012).
The same authors (Sun et al., 2012) also evaluate 
the antibacterial activity of compounds 18, 21, 22, 25, 
26, 29 on respect to the dendrimer size (G2 vs. G5) and 
exterior functionality (PO, SO and PEG) (Figure 6). In 
general, dendrimer G5 (21, 25, 29) were more effective 
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than G2 (18, 22, 26), and this behavior was attributed to 
the high density of diazeniumdiolates groups, which led 
to NO release close to the bacteria cells. In respect to the 
exterior functionality, dendrimer with SO on the surface 
(Figure 6) were the most effective, followed by PO and 
PEG (bacterial activity SO > PO > PEG) (Sun et al., 2012). 
Authors attributed this result to the association between 
the dendrimer surface and the cytoplasmic membrane 
of the bacteria (negatively charged), which is dependent 
on hydrophobic and electrostatic interactions, and thus 
favoring SO groups (more positive zeta potential and 
hydrophobicity) on the surface of dendrimers relative to 
PO and PEG (Sun et al., 2012).
According to the data described above, in general, 
the NO-releasing dendrimers exhibit low cytotoxicity 
and the biological assays showed that the activity of the 
different NO-donors was similar or improved after the 
attachment to dendrimers.
CONCLUSION
The combination of classical and new NO-donors 
with different materials allows to expand the field of pos-
sible applications for the NO molecule, constituting an at-
tractive therapeutic option. In general these strategies aim 
to solve the main challenge in NO-donor therapy: release 
a desired amount of NO at specific targets.
In this context, dendrimers are molecules which 
hold interesting properties to be used on the devel-
opment of NO-carrier systems. The possibility of 
surface functionalization of dendrimers with one or 
more molecules of interest can improve biocompat-
ibility, solubility and specificity of these systems, 
allowing the delivery of nitric oxide to targeted cells 
or tissues. Furthermore, according to the type of NO-
donor conjugated with the dendrimer (metal nitrosyl, 
diazeniumdiolates, S-nitrosothiols and new ones), the 
mechanism of NO release can be modified to fit a desired 
situation, like fast and large amount of NO released, or 
a low and continuous NO flow. Also, the mechanism 
involved in the nitric oxide release can be chosen ac-
cording to the purpose, from spontaneous to triggered.
The diverse NO-releasing dendrimers described in 
this review offers advantages and disadvantages, and ex-
hibit inherent characteristics regarding to the NO-release 
mechanism. This fact allows the choice of the most ap-
propriate NO-donor dendrimer and acts as a guide for the 
development of new NO-donors carriers. Also, the diverse 
biological applications tested so far with NO-releasing 
dendrimers show the potential uses of this system in dif-
ferent therapies and the new possibilities.
Another aspect that deserves attention is on regard 
to NO scavengers dendrimers. This topic has only briefly 
mentioned here as a consequence of a lack of literature 
on this regard. Certainly, synthetic aspects and biologi-
cal experiments aiming septic shock control will be quite 
welcome.
In this context, the use of dendrimers as NO carriers 
is a quite promising subject of research to be explored.
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